Challenges Persist for Pediatric Clinical Trials
TUESDAY, March 22, 2022 (HealthDay News) — Early discontinuation and nonreporting/nonpublication of findings continue to be common issues for conducting pediatric clinical trials, according to a study published online March 22 in Pediatrics.
Ryan Brewster, M.D., from the Stanford University School of Medicine in California, and colleagues characterized the prevalence of and factors associated with early discontinuation, results reporting, and publication of clinical trials enrolling participants
The researchers found that 11.1 percent of the trials were stopped early; the predominant reason for discontinuation was recruitment failure. Results were reported for 23.5 percent of completed trials; 38.8 percent were published within three years of completion. Over the study period, there was a significant improvement observed in rates of discontinuation and publication. The odds of discontinuation were lower for government-sponsored trials and academic trials versus industry trials (adjusted odds ratios, 0.72 and 0.64, respectively), and they were more likely to be published (adjusted odds ratios, 1.94 and 1.61, respectively). The likelihood of reporting results was lowest for academic trial investigators (adjusted odds ratio, 0.34).
“As the pediatric clinical trial ecosystem expands, so too must the mechanisms to address unique ethical, economic, and epidemiological barriers be prioritized,” the authors write. “Ultimately, addressing ongoing gaps in pediatric trial completion and availability of research findings will ensure that all children receive the highest quality, evidence-based care.”
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Learn MoreReview Explores Telehealth for Substance Use Disorders
TUESDAY, March 22, 2022 (HealthDay News) — The use of telehealth for the treatment of substance use disorders (SUDs) is addressed in a review and clinical practice guideline published online March 22 in the Annals of Internal Medicine.Stacey Uhl, fro…
Learn MoreMeds, Exercise Recommended for Stroke Prevention After sICAS
TUESDAY, March 22, 2022 (HealthDay News) — For patients with symptomatic intracranial atherosclerotic arterial stenosis (sICAS), initial treatment should comprise medications and exercise, and not percutaneous transluminal angioplasty and stenting, according to a practice advisory published online March 21 in Neurology.
Tanya N. Turan, M.D., from the Medical University of South Carolina in Charleston, and colleagues reviewed treatments for reducing the risk of recurrent stroke or death in patients with sICAS and developed recommendations for management. The resulting practice advisory has been endorsed by the American Heart Association/American Stroke Association, Neurocritical Care Society, and Society of Vascular and Interventional Neurology.
The authors note that clinicians should recommend 325 mg/d aspirin for long-term prevention of stroke and death; to further reduce stroke risk in patients with severe (70 to 99 percent) sICAS who have low risk of hemorrhagic transformation, addition of 75 mg/day clopidogrel to aspirin for up to 90 days is recommended. For patients with sICAS, clinicians should recommend high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol level
“Reviewing all of the evidence that has accumulated over the last two decades, we found that the research shows that medical management is more beneficial for people as an initial treatment,” Turan said in a statement.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Learn MoreExercise Intervention Evaluated in Young Cancer Patients
TUESDAY, March 22, 2022 (HealthDay News) — The Yo-Yo AD, an intermittent recovery test, can be used to assess the impact of a precision-based exercise intervention among children, adolescents, and young adults with hematologic malignancies, according…
Learn MoreEffectiveness of Ad26.COV2.S Vaccine Stable for Six Months
TUESDAY, March 22, 2022 (HealthDay News) — The vaccine effectiveness (VE) of Ad26.COV2.S was stable over six months, including during a period of delta variant predominance, according to a study published online March 17 in JAMA Network Open.Jennifer…
Learn MoreNo Myocarditis Recurrence After SARS-CoV-2 Vaccination
TUESDAY, March 22, 2022 (HealthDay News) — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination seems safe for patients with prior history of myocarditis, with no evidence of recurrence, according to a study presented at ESC Acute…
Learn MoreExtra Weight in Midlife Has Later Health, Cost Effects
TUESDAY, March 22, 2022 (HealthDay News) — Being overweight in midlife is associated with long-term adverse health and economic consequences in older adulthood, according to a study published online March 15 in JAMA Network Open.Sadiya S. Khan, M.D.,…
Learn MoreAI Model Predicts Colorectal Cancer Risk in Younger Adults
TUESDAY, March 22, 2022 (HealthDay News) — Machine learning can use electronic health record (EHR) data to predict colorectal cancer (CRC) risk in adults 35 to 50 years of age, according to a study published online March 10 in PLOS ONE.
Hisham Hussan, M.D., from The Ohio State University in Columbus, and colleagues developed a prediction model using machine learning and EHR-derived factors to identify individuals aged 35 to 50 years who may benefit from early CRC screening. Analysis of the model’s effectiveness included 30 percent of 3,116 adults aged 35 to 50 at average risk for CRC who underwent colonoscopy between 2017 and 2020 at a single center, while the remaining 70 percent were used to develop the model.
The researchers found that all four machine learning models predicted CRC with higher discriminative ability versus the reference model (C-statistics [95 percent confidence intervals]: neural network, 0.75 [0.48 to 1.00] versus reference, 0.43 [0.18 to 0.67]; P = 0.07). Three of the four machine learning approaches (except for gradient boosting) predicted CRC or high-risk polyps significantly better than the reference model (regularized discriminant analysis, 0.64 [0.59 to 0.69] versus reference, 0.55 [0.50 to 0.59]; P
“Further development of our model is needed, followed by validation in a primary-care setting, before clinical application,” the authors write.
Learn MoreMany Youth Overdosing on Benzos, Stimulants Have Recent Rx
TUESDAY, March 22, 2022 (HealthDay News) — A considerable proportion of youth with overdoses involving benzodiazepines (BZDs) or stimulants have recent prescriptions for these medications, according to a study published online March 2 in Pediatrics.I…
Learn MoreAHA News: Los flavonoides son una sabrosa manera de mejorar la salud del corazón y del cerebro
MARTES, 22 de marzo de 2022 (American Heart Association News) — ¿Qué tienen en común las moras azules, la espinaca y el chocolate amargo?Todos son ricos en flavonoides, los compuestos químicos que dan color – y poderes medicinales – a las plantas. In…
Learn More